Efficacy and safety of recombinant E-coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group

Autor: Gertjan J.L. Kaspers, Hans Jürgen Kühnel, Wim J. E. Tissing, Rob Pieters, Cor van den Bos, Marc Bierings, Wouter J.W. Kollen, Thorsten König, Maroeska te Loo, Uwe Pichlmeier, Inge M. van der Sluis, Hester A. de Groot-Kruseman

Publikováno v: Pediatric Blood & Cancer, 65,
Pediatric blood & cancer, 65(8):e27083. Wiley-Liss Inc.
Pediatric Blood & Cancer, 65, 8, pp.
van der Sluis, I M, de Groot-Kruseman, H, te Loo, M, Tissing, W J E, van den Bos, C, Kaspers, G J L, Bierings, M, Kollen, W J W, König, T, Pichlmeier, U, Kühnel, H-J R & Pieters, R 2018, ' Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group ', Pediatric Blood and Cancer, vol. 65, no. 8, e27083 . https://doi.org/10.1002/pbc.27083
Pediatric Blood and Cancer, 65(8):e27083. Wiley-Liss Inc.
Pediatric Blood & Cancer, 65(8):e27083. Wiley-Liss Inc.
Pediatric Blood and Cancer, 65. Wiley-Liss Inc.

Background: The efficacy and safety of recombinant Escherichia coli–asparaginase (rASNase) was compared to native E.coli asparaginase (Asparaginase medac). Methods: One hundred and ninety-nine children with newly diagnosed acute lymphoblastic leuke

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a70e6d0e1721cd3f207506c158149597
https://pure.eur.nl/en/publications/50617fc8-1f22-4ff4-a6f5-e80af6502b23

Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials

Autor: Anja Möricke, Thorsten König, Joachim Gerß, Martin Schrappe, Hans-Jürgen Kühnel, Claudia Lanvers-Kaminsky, Dieter Franke, Arendt von Stackelberg, Günter Henze, Andrea Willer, Joachim Boos

Publikováno v: Blood. 118(22)

Hypersensitivity reactions limit the use of the antileukemic enzyme asparaginase (ASE). We evaluated Ab levels against Escherichia coli ASE and ASE activity in 1221 serum samples from 329 patients with acute lymphoblastic leukemia who had received AS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e320b7a8d90e4ae1acd4784ad9da7d2b
https://pubmed.ncbi.nlm.nih.gov/21940824